fda tirzepatide ruling court on US judge denies injunction, restricting copies of Lilly weight-loss drug Tirzepatide, FDA, and Compounding: Understanding – Mounjaro will remain off shortage

Zepbound (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that is FDA-approved along with increased physical activity and a reduced-calorie diet for chronic weight management in adults with a starting body mass index (BMI) of: 30 kg/m^2 or higher (obesity) 27 kg/m^2 or higher (overweight) with at least one weight-related condition such as high cholesterol, high blood pressure (hypertension), type 2 diabetes, heart disease, or obstructive sleep apnea

It varies in appearance anywhere from a clear, colorless liquid to slightly yellow in color

According to a company statement, there have been hundreds of reports submitted to the FDAs voluntary adverse event reporting system related to compounded semaglutide

Dehydration raises nausea risk and can cause other issues, so make fluids a priority

Larger nodules may occasionally cause compressive symptoms such as difficulty swallowing, a sensation of pressure in the neck, or hoarseness if they affect the recurrent laryngeal nerve